Imaging Test Using Rubidium-82 PET to Grade Kidney Cancer
Tests a rubidium-82 PET scan to help grade kidney cancer in adults.
Plain-language title generated from the registry record
Registry title: Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
Key facts
- Where
- Paris, FranceSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a kidney tumor that is likely or confirmed to be kidney cancer and needs surgery. It tests whether a special PET scan can show how aggressive the cancer is.
- Age
- 18 to 90 years
- Sex
- All sexes can join.
- Disease stage
- Kidney tumor 2 cm (0.8 in) to 7 cm (2.8 in) across, with clear cell features on CT imaging. Cancer growing outside the kidney (cT3b, cT3c, cN+ or M+) is excluded.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Hereditary forms of kidney cancer (VHL, MET, FH, FLCN)
- Contraindication to PET-CT or to 82-Rb injection
- Only one kidney from birth (unilateral renal agenesis) or multicystic renal dysplasia
- Tumors with high suspicion of spread outside the kidney
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07346404, who can take part
Where in France
- Assistance Publique Hopitaux de ParisParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07346404EU 2024-514085-39-00
- Record updated
- 16 January 2026
- Original description
This is a pilot prospective longitudinal monocentric, non-comparative, nonrandomised, and non-controlled open study.Read full original descriptionShow less
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
This is a pilot prospective longitudinal monocentric, non-comparative, nonrandomised, and non-controlled open study.
is to test whether the intensity of 82-Rb uptake on PET acquisitions is associated to the aggressiveness of RCC on histology (ISUP grades), i.e., to successfully identify high-grade (ISUP grades 3 and 4) vs. lowgrade (ISUP grades 1 and 2) RCC.
Inclusion: Age ≥ 18 years old; Signed written informed consent; French Social Security affiliation; Patients with high suspicion of or confirmed RCC requiring surgical resection; Kidney tumor diameter between 2 cm and 7 cm with clear cell imaging feature (hyper vascular lesion with contrast-enhancement similar to the renal cortex on CTA); Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion: Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable; Pregnant or breastfeeding women; Patient under legal protection (guardianship); Contraindication to the PET-CT; Contraindication to the injection of 82-Rb; Patient on SMA (state medical aid); Unilateral renal agenesis; Multicystic renal dysplasia; Hereditary forms of RCC as VHL, MET, FH and FLCN; Bosniak 3 cysts; Hypovascular lesions with enhancement inferior to the renal cortex in corticomedullary-phase images on CTA; Exclusion of clear renal cell adenocarcinoma on biopsy; Kidney tumors with high suspicion of extra-renal extension (cT3b, cT3c, cN+ or M+).